[ET Net News Agency, 18 February 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said its subsidiary Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu
Hansoh Pharmaceutical Group Company Ltd. (collectively, the licensees) have entered into
an exclusive licence and collaboration agreement with SCYNEXIS, Inc. (NASDAQ: SCYX).
The licensees will obtain an exclusive licence from SCYNEXIS to research, develop and
commercialize ibrexafungerp in the People's Republic of China. In consideration for the
exclusive licence, the licensees agree to pay to SCYNEXIS an upfront payment of US$10
million plus potential milestone payments and royalties.
The product is a first-in-class, novel triterpenoid antifungal agent with broad-spectrum
activity providing the therapeutic advantages of both intravenous and oral formulations.
(RC)